Trevi Therapeutics (TRVI) stock forecast for 2027
Last update: 05-27-2022, 6:04Sector: Healthcare
The share price of Trevi Therapeutics, Inc. (TRVI) now
What analysts predict:: $8.67
52-week high/low: $3.731 / $0.46
50/200 Day Moving Average: $2.377 / $1.425
This figure corresponds to the average price over the previous 50/200 days. For Trevi Therapeutics stocks, the 50-day moving average is the support level today.
For Trevi Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in Trevi Therapeutics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Trevi Therapeutics stock price in 2027. How much will one Trevi Therapeutics share be worth in 2027?
Is it worth taking profit / loss on Trevi Therapeutics stock now or waiting? What are analysts' forecasts for Trevi Therapeutics stock?
We forecast Trevi Therapeutics stock performance using neural networks based on historical data on Trevi Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Trevi Therapeutics stock prediction results are shown below and presented as a graph, table and text information.
Trevi Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Trevi Therapeutics analysts is $8.67.
Today 200 Day Moving Average is the support level (1.425 $).
50 Day Moving Average is the support level (2.377 $).
Historical and forecast chart of Trevi Therapeutics stock
The chart below shows the historical price of Trevi Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Trevi Therapeutics stock price can be found in the table below.
Trevi Therapeutics (TRVI) Forecast for 2027
Trevi Therapeutics information and performance
Trevi Therapeutics Inc. is a clinical biopharmaceutical company focused on the development and commercialization of Nalbuphine ER for the treatment of neurologically mediated conditions. The company is developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LD), in patients with Parkinson’s disease. The company is conducting phase 2b/3 clinical trials for nalbuphine ER. The company has also initiated a phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics, and antipruritic effect of nalbuphine ER in this population. The Company’s nalbuphine development programs for ER include the Chronic Pruritus Program, the Nodular Pruritus Program, the Chronic Liver Disease Pruritus Program, and the Uremic Pruritus Program.
Trevi Therapeutics Address
195 CHURCH STREET, 14TH FLOOR, NEW HAVEN, CT, US
Market Capitalization: 87 043 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -23 079 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: -
Enterprise Value (EV) /Revenue
EV To EBITDA: 0.0232
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 38685600
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Trevi Therapeutics price target for 2021 by month
Target values for the price of one Trevi Therapeutics share for Jan 2027.
Pessimistic target level: 8.52
Optimistic target level: 12.06
Target values for the price of one Trevi Therapeutics share for Feb 2027.
Pessimistic target level: 11.15
Optimistic target level: 13.90
Target values for the price of one Trevi Therapeutics share for Mar 2027.
Pessimistic target level: 13.55
Optimistic target level: 16.83
Target values for the price of one Trevi Therapeutics share for Apr 2027.
Pessimistic target level: 10.60
Optimistic target level: 15.66
Target values for the price of one Trevi Therapeutics share for May 2027.
Pessimistic target level: 14.70
Optimistic target level: 19.35
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.